Haemonetics (FRA:HAZ) Current Deferred Revenue: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HAZ Haemonetics Corp FRA:HAZ
84 GF Score
Price €78.00
GF Value €73.15
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Haemonetics Current Deferred Revenue?

Haemonetics FRA:HAZ 84 Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus rates FRA:HAZ with a GF Score™ of 84/100 and a GF Value™ of €73.15 (Fairly Valued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Haemonetics's current deferred revenue for the quarter that ended in Jun. 2026 was €0 Mil.

Haemonetics Current Deferred Revenue Related Terms

Haemonetics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Haemonetics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Current Deferred Revenue Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.34 28.22 28.74 40.10 36.60

Haemonetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 36.60 0.00
FRA:HAZ
84GF Score
Haemonetics Corp FRA:HAZ
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0 Mil mean?
Haemonetics (FRA:HAZ) has a Current Deferred Revenue of €0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Haemonetics and its competitors.
Is Haemonetics' Current Deferred Revenue too high?
Haemonetics' current Current Deferred Revenue is €0 Mil. Overall, Haemonetics has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Current Deferred Revenue compare to IRTC and ITGR?
Haemonetics' Current Deferred Revenue of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Haemonetics and its competitors. Haemonetics's current Current Deferred Revenue is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (FRA:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €73.15, compared to a current price of €78.00 — trading 6.6% above its estimated fair value. The current Current Deferred Revenue is €0 Mil. Haemonetics' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Haemonetics (FRA:HAZ), the current Current Deferred Revenue is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (FRA:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued. The current stock price of €78.00 is trading 6.6% above its estimated GF Value™ of €73.15. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for FRA:HAZ:

  • Current Deferred Revenue: €0 Mil
  • GF Value™: €73.15 vs. price of €78.00 (6.6% above fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the FRA:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
84GF Score

Get the complete analysis for FRA:HAZ

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€73.15
GF Value